Today’s guest is Dr. Hugh Young Rienhoff, Jr., a San Francisco Bay Area clinical physician-scientist and entrepreneur. He serves as the CEO and a Founder of Imago BioSciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. In November 2022, Merck announced that it was acquiring Imago. They are using a differentiated pathway and mechanism of action to target MPNs, particularly MF, ET and PV. Imago is pioneering a novel Lysine-Specific Demethylase-1 (LSD1) inhibitor called Bomedemstat that’s showing a lot of promise -- and is at the doorstep of Phase 3 trials for MF and ET. We discuss their positive clinical data, patient clinical studies and unique approach that may impede natural disease progression and offer a new weapon against MPNs.